Compare Natera Inc. Common Stock (NTRA) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Realty Income Corp — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Realty Income Corp trades at $55.64 (market cap $52.03B). The key difference: Natera Inc. Common Stock and Realty Income Corp are close in size by market cap, and Realty Income Corp pays a 5.92% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Realty Income Corp for 128 Days on average.
| NTRA | O | |
|---|---|---|
Market Cap | $57.03B | $52.03B |
Volume | 1,131,157 | 16,838,213 |
Sector | Health | Real Estate |
52-Week High | $425.64 | $67.56 |
52-Week Low | $179.42 | $53.35 |
Typical Hold Time | 0 Days | 128 Days |
Enterprise Value | $56.18B | $82.66B |
Dividend Yield | — | 5.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Realty Income (O) trades at $54.99, up 0.53% on the day, but remains in a bearish technical trend amid recent earnings misses. The stock's valuation appears elevated with a P/E of 40.14 and P/S of 8.53, though profitability is strong with a 92.56% gross margin. Recent news highlights the stock's decline as Treasury yields rise, pressuring REIT valuations, while the company maintains a robust dividend history with consistent monthly payouts.
Outlook: Moderate upside to the $64.16 consensus price target exists, supported by solid fundamentals and high analyst buy ratings, but risks include interest rate sensitivity, debt growth, and competitive pressures. The stock offers income appeal but faces near-term headwinds from macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
